Myotube growth is associated with cancer-like metabolic reprogramming and is limited by phosphoglycerate dehydrogenase.

Glycolysis Hypertrophy Insulin-like growth factor I Metabolism Skeletal muscle Warburg effect

Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
15 Dec 2023
Historique:
received: 30 06 2022
revised: 10 10 2023
accepted: 14 10 2023
pubmed: 26 10 2023
medline: 26 10 2023
entrez: 25 10 2023
Statut: ppublish

Résumé

The Warburg effect links growth and glycolysis in cancer. A key purpose of the Warburg effect is to generate glycolytic intermediates for anabolic reactions, such as nucleotides → RNA/DNA and amino acids → protein synthesis. The aim of this study was to investigate whether a similar 'glycolysis-for-anabolism' metabolic reprogramming also occurs in hypertrophying skeletal muscle. To interrogate this, we first induced C2C12 myotube hypertrophy with IGF-1. We then added

Identifiants

pubmed: 37879549
pii: S0014-4827(23)00371-3
doi: 10.1016/j.yexcr.2023.113820
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113820

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Auteurs

Lian E M Stadhouders (LEM)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.

Jonathon A B Smith (JAB)

School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK; Department of Physiology and Pharmacology (FYFA), Group of Integrative Physiology, Karolinska Institutet, Stockholm, Sweden.

Brendan M Gabriel (BM)

Aberdeen Cardiovascular & Diabetes Centre, The Rowett Institute, University of Aberdeen, Aberdeen, UK.

Sander A J Verbrugge (SAJ)

Exercise Biology, Department for Sport and Health Sciences, Technical University of Munich, Georg-Brauchle-Ring 60/62, 80992, München/Munich, Germany.

Tim D Hammersen (TD)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.

Detmar Kolijn (D)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands; Department of Clinical Pharmacology and Molecular Cardiology, Ruhr University Bochum, Bochum, Germany.

Ilse S P Vogel (ISP)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.

Abdalla D Mohamed (AD)

School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK; Cancer Therapeutics Unit, Target Genomic and Chromosomal Instability, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK.

Gerard M J de Wit (GMJ)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.

Carla Offringa (C)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.

Willem M H Hoogaars (WMH)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.

Sebastian Gehlert (S)

Department for the Biosciences of Sports, Institute of Sports Science, University of Hildesheim, Universitätsplatz 1, 31141, Hildesheim, Germany; Department for Molecular and Cellular Sports Medicine, German Sport University Cologne, 50933, Cologne, Germany.

Henning Wackerhage (H)

Exercise Biology, Department for Sport and Health Sciences, Technical University of Munich, Georg-Brauchle-Ring 60/62, 80992, München/Munich, Germany.

Richard T Jaspers (RT)

Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands. Electronic address: r.t.jaspers@vu.nl.

Classifications MeSH